BioNTech, UPenn Settle Patent Suit Over Covid-Shot Royalties

BioNTech SE and the University of Pennsylvania settled a federal lawsuit in which Penn sought a greater share of $75 billion in Comirnaty’s global sales for patented mRNA technology crucial for the Covid-19 vaccine.

The agreement doesn’t allow either side to renew its allegations, according to Judge Kai N. Scott’s dismissal order docketed Thursday in the US District Court for the Eastern District of Pennsylvania. The case had been paused since January, after the parties told the court they needed time to finish negotiating a deal.

• Penn sued BioNTech in August 2024 alleging BioNTech underpaid royalties by limiting payments to ...